Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1117737 | 0.87 | TSHR (0.55) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL7263832 | 0.81 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL28546165 | 0.81 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL194803 | 0.79 | TSHR (0.57) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL11687302 | 0.77 | TSHR (0.55) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL10386400 | 0.76 | IDO1 (0.37) | TSHRIDO1AGXTALDH1A1L3MBTL1 | |
| SCHEMBL6035596 | 0.76 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL77609 | 0.76 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL2257325 | 0.76 | TSHR (0.43) | TSHRIDO1AGXTALDH1A1L3MBTL1 | |
| SCHEMBL51153 | 0.75 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320552-B | Puerarin derivative with good biological activity and preparation method and application thereof | 浙江药苑生物科技有限公司 | 2020-10-16 | — | — | CN | claimed |
| US-12358919-B2 | Antibacterial compounds | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2025-07-15 | — | — | US | disclosed |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | TRILINK BIOTECHNOLOGIES, LLC | 2025-06-26 | — | — | US | disclosed |
| EP-4499824-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023183569-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023108296-A1 | ISOPROPYLAMINE ANALOGUES OF PHOSPHORYLATED AND SULFONATED MESCALINE DERIVATIVES | Enveric Biosciences Canada Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023044574-A1 | PHOSPHORYLATED AND SULFONATED MESCALINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-03-30 | — | — | WO | disclosed |
| US-20220235059-A1 | ANTIBACTERIAL COMPOUNDS | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2022-07-28 | — | — | US | disclosed |
| EP-3980418-A1 | ANTIBACTERIAL COMPOUNDS | Universita' Degli Studi di Siena (IT) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022019021-A1 | CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE | 株式会社伏見製薬所 | 2022-01-27 | — | — | WO | disclosed |
| WO-2002085848-A3 | SYNTHESIS OF PANCRATISTATIN PRODRUGS | UNIV ARIZONA STATE (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-1278758-A1 | COMBRETASTATIN A-1 PHOSPHATE AND COMBRETASTATIN B-1 PHOSPHATE PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002085848-A2 | SYNTHESIS OF PANCRATISTATIN PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1045853-A4 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | UNIV ARIZONA STATE (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001081355-A1 | COMBRETASTATIN A-1 PHOSPHATE AND COMBRETASTATIN B-1 PHOSPHATE PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA,ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1045853-A1 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035150-A1 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | ARIZONA BOARD OF REGENTS, A BODY CORPORATE, ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1999-07-15 | — | — | WO | disclosed |
| US-4242479-A | CATALYST OF ALUMINUM TRIHALIDE, ORGANOSILOXANE COMPOUND OR ETHER, MAGNESIUM ALCOHOLATE, TITANIUM-HALOGEN AND ORGANOALUMINUM COMPOUNDS | SHOWA YUKA KABUSHIKI KAISHA (JP) | 1980-12-30 | — | — | US | disclosed |
| US-4180636-A | MAGNESIUM HALIDE, TITANIUM COMPOUND ELECTRON DONOR COMPOUND, TRIALKYL ALUMINUM CATALYST | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1979-12-25 | — | — | US | disclosed |
| US-4163781-A | 3-Amino-N-[(phosphonoamino)iminomethyl]-6-halopyrazinecarboxamide compounds, compositions and methods of use | MERCK & CO., INC. (US) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358919-B2 | Antibacterial compounds | ABCB11, CFTR, MRPL21 | TSHR 4772/4885IDO1 1087/4885AGXT 740/4885 |
| US-20220235059-A1 | ANTIBACTERIAL COMPOUNDS | ABCB11, CFTR, MRPL21 | TSHR 4772/4885IDO1 1087/4885AGXT 740/4885 |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | RNGTT, POLRMT, POLN | TSHR 2116/4885IDO1 3983/4885AGXT 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.